about
Metabolic effect of telmisartan and losartan in hypertensive patients with metabolic syndromeEffect of long-acting testosterone treatment on functional exercise capacity, skeletal muscle performance, insulin resistance, and baroreflex sensitivity in elderly patients with chronic heart failure a double-blind, placebo-controlled, randomized sUric acid lowering therapy in cardiovascular diseases.Dynamic adaptation of cardiac baroreflex sensitivity to prolonged exposure to microgravity: data from a 16-day spaceflight.Symptoms and quality of life in heart failure: the muscle hypothesis.Aetiology and pathophysiological implications of oscillatory ventilation at rest and during exercise in chronic heart failure. Do Cheyne and Stokes have an important message for modern-day patients with heart failure?ISMAR-study presentation: in-hospital epidemiology and clinical management of respiratory and cardiac comorbidities in cardiac and respiratory disease units.Bibliometric analysis of literature in cerebrovascular and cardiovascular diseases rehabilitation: growing numbers, reducing impact factor.Testosterone replacement in hypogonadal men with type 2 diabetes and/or metabolic syndrome (the TIMES2 study).Metabolic therapy for the diabetic patients with ischaemic heart disease.Physiological basis for contractile dysfunction in heart failure.Role of genetic polymorphisms of ion channels in the pathophysiology of coronary microvascular dysfunction and ischemic heart disease.Efficacy and safety of mineralocorticoid receptors in mild to moderate arterial hypertension.Circulating biomarkers in pulmonary arterial hypertension: update and future direction.Telemedicine for cardiovascular disease continuum: A position paper from the Italian Society of Cardiology Working Group on Telecardiology and Informatics.Eplerenone in chronic heart failure with depressed systolic function.Pharmacological Management of Chronic Stable Angina: Focus on Ranolazine.Therapeutic options of Angiotensin Receptor Neprilysin inhibitors (ARNis) in chronic heart failure with reduced ejection fraction: Beyond RAAS and sympathetic nervous system inhibition.In COPD patients on prolonged mechanical ventilation heart rate variability during the T-piece trial is better after pressure support plus PEEP: a pilot physiological study.Ranolazine improves insulin resistance in non-diabetic patients with coronary heart disease. A pilot study.Estrogen acutely increases peripheral blood flow in postmenopausal women.Incidence and clinical presentation of myocardial ischemia in patients with chronic CAD in Italy: the ISPICA survey study.Initiating sacubitril/valsartan (LCZ696) in heart failure: results of TITRATION, a double-blind, randomized comparison of two uptitration regimens.Comparison of effectiveness of carvedilol versus bisoprolol for prevention of postdischarge atrial fibrillation after coronary artery bypass grafting in patients with heart failure.Testosterone therapy in women with chronic heart failure: a pilot double-blind, randomized, placebo-controlled study.Effectiveness of nebivolol and hydrochlorothiazide association on blood pressure, glucose, and lipid metabolism in hypertensive patients.On-target antihypertensive treatment in Italy: the ISPIT (Indagine Sicoa Paziente Iperteso a Target) survey study.Effect of trimetazidine on quality of life in elderly patients with ischemic dilated cardiomyopathy.Chromogranin A in heart failure; a novel neurohumoral factor and a predictor for mortality.Effects of testosterone on the Q-T interval in older men and older women with chronic heart failure.Anticoagulation in "real world" patients with atrial fibrillation in Italy: results from the ISPAF (Indagine Sicoa Paziente Con Fibrillazione Atriale) survey study.Incidence of atrial fibrillation in an Italian population followed by their GPs through a telecardiology service.[Role of regulatory authorities in healthcare delivery for the elderly].Trimetazidine improves left ventricular function and quality of life in elderly patients with coronary artery disease.Comparison of trimetazidine plus sildenafil to chronic nitrates in the control of myocardial ischemia during sexual activity in patients with coronary artery disease.Effect of High-Intensity interval training versus moderate continuous training on 24-h blood pressure profile and insulin resistance in patients with chronic heart failure.Effects of chronic testosterone administration on myocardial ischemia, lipid metabolism and insulin resistance in elderly male diabetic patients with coronary artery disease.Dose-response relationship of autonomic nervous system responses to individualized training impulse in marathon runners.Metformin improves endothelial function in patients with metabolic syndrome.Metabolic agents in the management of diabetic coronary patients: a new era.
P50
Q24816197-142BC7C1-CF77-43A9-9D6B-5A6E112D6C9AQ28256618-75029FF3-7253-403B-8C79-FC7D8E6FE300Q30252087-8AC58A09-8FCC-4409-9912-450C5A9DBBEDQ33364693-7AC1118F-8C44-4F99-91EB-383048840090Q33614245-A1FA98E5-BCD7-481E-9CED-8EDF9C0F4EB4Q33653331-9A4CAD56-D97D-49D9-AA52-F6B89219F914Q33687087-DCE24C85-49FA-4BD0-B7CA-3867E64692F9Q34393563-B82E1200-3C62-4374-9FDE-E006FB9E08FDQ34718357-AC23FECD-DD9B-4B69-9F75-449C852A3052Q36337453-7E8D03CC-4517-45D7-89C8-E2B71FBA292FQ37320392-9E92620A-8251-4CDF-AE98-BC12ED3D3F0FQ37501931-8773943B-A819-48C7-9087-5740D44E04CDQ38281539-DF91E85B-EC74-46E6-A916-C680340AB56EQ38355960-9A75FC8A-0DB2-4605-AF3D-A5D4828924AEQ38371358-F0659BC8-188A-4A28-ADEE-4824BD25DB59Q38516197-CD70F522-66AA-43A3-BF76-2E09CE7F85B1Q38841829-1DD516F2-D1C7-48A3-BA2A-9AE6B90CBBEEQ38866654-CA07FDD4-2FCB-4BE6-8F27-9AD21CE2A73CQ39187429-798D9C64-FDAA-45AD-9848-1425F57CE57CQ39669941-97B00174-95F7-4FFB-8044-70A8FABB371DQ40977120-B2AE533F-7C7D-4AA4-9357-254FAD05241CQ41023077-3CCF2938-7D9C-4021-B21A-C42BC516ECF1Q41607888-B4DA28D5-2B66-4499-8C86-7D695280E77BQ42786276-AFF29CA4-B93F-4E26-B421-5A00E8FB23B3Q42871399-E778DCE5-D007-45E4-A9DE-6473DFEBB39BQ42944574-3285B93A-F727-4E56-9CED-DFE417D36711Q43919551-42D44DEE-2966-4462-88C9-D7251F0AC020Q43995359-C2E9D2ED-47A3-4315-A7E2-E2E92B853150Q44031331-1041D37F-8781-4D47-9CA9-160D2B6D1CB1Q44080022-530F7255-0CCA-49DE-9D49-57878C006452Q44511543-7FA43E7B-F865-4CDC-BCD8-0870F9727C68Q44697209-918DF57C-0475-418E-8F0A-7A5E59E3298AQ44809152-0C964A40-013E-4026-A125-345B09F99B8FQ45098724-FDF1604F-E527-47FC-AD5D-89E0B6131C89Q45238079-C31D3BD8-4076-4BC7-BE4F-299FD4C6ADD0Q45849141-B20642BF-BB7D-4D69-8B4A-D73EBBE80DEAQ46053516-1DD8D499-F396-410E-A42B-42D9A7A8A3B8Q46070265-9BD0B851-DDDC-46C0-8855-539AA629B745Q46663023-6670549D-2026-4810-9F28-58F5839E4400Q46805150-358414CC-5535-46C3-9D74-A4CF19C0E4E9
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Maurizio Volterrani
@ast
Maurizio Volterrani
@en
Maurizio Volterrani
@es
Maurizio Volterrani
@nl
type
label
Maurizio Volterrani
@ast
Maurizio Volterrani
@en
Maurizio Volterrani
@es
Maurizio Volterrani
@nl
prefLabel
Maurizio Volterrani
@ast
Maurizio Volterrani
@en
Maurizio Volterrani
@es
Maurizio Volterrani
@nl
P106
P1153
7004062259
P31
P496
0000-0002-2624-9213